Vqure Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Vqure Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, grow…

2016-11-30 Thane, Maharashtra Active Unlisted Active Compliant
Share
Connect MCP
VP Vqure Pharmaceuticals Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Vqure Pharmaceuticals Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
55/100
Trust Score
Moderate

Vqure Pharmaceuticals Private Limited is assessed as Moderate with a Trust Score of 55/100. Vqure Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 2016, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 27 Jul 2026 from the latest processed filings. Vqure Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
55/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
75/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
10/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
30/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 50/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 75/100 Low Risk
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2023 - filings overdue.
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
SHIVAKANT MISHRA 01234567 Director 01/04/2018 6 yrs Approved
VIRENDRA DAYASHANKAR MISHRA 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
0 allotment(s) · 4 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 70 · Distress 30
Growth signals & trust indicators
Revenue acceleration: +38% over 4 year(s).
Operating for 9 years.
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Negative net worth.
Statutory filings appear overdue.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence56/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 4 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment44/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view45/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 12 events
30 Sep 2023
Last AGM held
Annual general meeting
31 Mar 2023
Latest balance sheet
Filed with ROC
31 Mar 2022
Share transfer (FY 2022)
4000.00000000 shares to Mishra Gayatri Prasad Shivakant
24 Dec 2021
Director ceased
SIRISHA JAGADISH KUMAR VADDI
31 Mar 2019
Share transfer (FY 2019)
2000.00000000 shares to Shivakant Mishra
Share transfer (FY 2019)
1000.00000000 shares to Sirisha Jagdish Vaddi
Share transfer (FY 2019)
3000.00000000 shares to Sirisha Jagdish Vaddi
01 Aug 2018
Director appointed
SHIVAKANT MISHRA (Director)
Director ceased
SACHIV KASHINATH SHUKLA
Director ceased
ABHISHEK SHRIPRKASH MISHRA
30 Nov 2016
Incorporated
Registered with Roc Mumbai
Director appointed
VIRENDRA DAYASHANKAR MISHRA (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Nebras Exim Private Limited U51909MH2021PTC359528 Mumbai, Maharashtra, India
Techmatters Systems And Services Private Limited U72300WB2015PTC207567 Kolkata, West Bengal, India
Agasthya Nutro Milk Private Limited U74999TG2020PTC147101 Golconda, Telangana, India
5 Elements Enterprises Private Limited U74999DL2019PTC346668 Delhi, Delhi, India
Apindex Pharmaceuticals Private Limited U24100GJ2021PTC125403 Surat, Gujarat, India
Purewin Trendz Private Limited U18202GJ2021PTC127915 Surat, Gujarat, India
Medissist Pharma Private Limited U74999DL2016PTC306024 New Delhi, Delhi, India
Suri Overseas Private Limited U17100DL1981PTC012319 New Delhi, Delhi, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Vqure Pharmaceuticals Private Limited before audits and certifications: compliance score 75/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Vqure Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Enhanced diligence advised. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 70/100, margin trends, ownership structure and peer set for Vqure Pharmaceuticals Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 55/100, distress signals and MSME payment-delay disclosures - know whether Vqure Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Vqure Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Vqure Pharmaceuticals Private Limited an active company?

Vqure Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 75/100 (Low Risk).

Is Vqure Pharmaceuticals Private Limited financially healthy?

Vqure Pharmaceuticals Private Limited has a Financial Health Score of 10/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Vqure Pharmaceuticals Private Limited?

Its overall Trust Score is 55/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Vqure Pharmaceuticals Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Vqure Pharmaceuticals Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Vqure Pharmaceuticals Private Limited up to date with its ROC filings?

Last balance sheet is for Mar 2023 - filings overdue. Overall compliance score: 75/100 (Low Risk).

Is it risky to lend to Vqure Pharmaceuticals Private Limited?

Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Enhanced diligence advised.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.